12
Feb

Looking to wrap up its package of data to present to the FDA on its anal pain drug VEN 307, Ventrus Biosciences instead wound up with a failed Phase III study as a high placebo response wiped out the efficacy advantage that they were expecting.

…read more

Source: Ventrus takes a beating, blames placebo effect for PhIII pain failure

    

0 No comments